XML 77 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Partnerships - Additional Information (Details)
¥ in Billions
 1 Months Ended 12 Months Ended 31 Months Ended
Dec. 31, 2022
USD ($)
May 31, 2017
USD ($)
Dec. 31, 2022
USD ($)
Nov. 30, 2019
shares
Mar. 16, 2023
USD ($)
Mar. 16, 2023
JPY (¥)
Dec. 05, 2022
USD ($)
Dec. 05, 2022
JPY (¥)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue current $ 14,700,000   $ 14,700,000          
Deferred revenue long term 10,378,000   10,378,000          
Recognized revenue     15,759,000          
Ono | Asset Purchase Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Upfront non-refundable and non-creditable payment receivable, upon exchange of option             $ 26,400,000 ¥ 3.5
Foreign curreny realized gain 600,000              
Upfront payment received 26,400,000              
Upfront non-refundable and non-creditable payment invoiced             25,800,000 ¥ 3.5
Upfront and non-creditable payment invoiced             25,800,000  
Estimated research and development funding             76,800,000  
Initial transaction price             102,600,000  
Deferred revenue 25,100,000   25,100,000       $ 25,800,000  
Deferred revenue current 14,700,000   14,700,000          
Deferred revenue long term 10,400,000   10,400,000          
Proceeds from research and development fees $ 12,200,000              
Recognized revenue     $ 15,800,000          
Option period expiry condition     he option period will expire three months following the delivery of topline data from the EQUALISE clinical study in lupus nephritis and interim data from the EQUATOR Phase 3 clinical study in acute graft-versus-host disease.          
Ono | Asset Purchase Agreement | Subsequent Event                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
One-time payment receivable, upon exercises the option         $ 37,200,000 ¥ 5.0    
Ono | Asset Purchase Agreement | Maximum | Subsequent Event                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Eligible to receive payment on achievement of certain development milestones         $ 101,400,000      
Biocon                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Common stock shares issued | shares       2,316,134        
Biocon | Collaboration and License Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Regulatory milestone payments   $ 30,000,000            
Sales milestone payments   $ 565,000,000            
Research and Development Services | Ono | Asset Purchase Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Recognized revenue     $ 11,800,000          
Upfront Payment Amortization | Ono | Asset Purchase Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Recognized revenue     $ 4,000,000.0